XML 32 R15.htm IDEA: XBRL DOCUMENT
v3.21.1

REVENUE | 12 Months Ended
--- | ---
Dec. 31, 2020
REVENUE |
REVENUE | NOTE 8 - REVENUE The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended December 31,
(U.S. dollars in thousands) | ​ | 2018 | ​ | 2019 |  | 2020
Pfizer | ​ | $ | 5,320 | ​ | $ | 6,722 | ​ | $ | 8,105
Brazil | ​ | $ | 3,658 | ​ | $ | 9,144 | ​ | $ | 8,000
Chiesi | ​ | ​ | - | ​ | ​ | - | ​ | $ | 131
Total revenues from selling goods | ​ | $ | 8,978 | ​ | $ | 15,866 | ​ | $ | 16,236
Revenues from license and R&D services | ​ | $ | 25,262 | ​ | $ | 38,827 | ​ | $ | 46,662
​ During the year ended December 31, 2020, the Company recorded revenue in the amount of $12.8 million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements.

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration